THURSDAY, May 8 - Workshops
Morning Sessions
THURSDAY, May 8 - Morning Sessions
Workshops
08:15-09:00
Morning Coffee | Registration (check-in/badge pick-up)
09:00-10:30
3D Structure-based Drug Design and Virtual Screening 
Anh-Tien Ton, Senior Applications Scientist, Chemical Computing Group
10:30-11:00
Morning Break
11:00-12:00
2D Combinatorial Library Design and SAR Analysis 
Valérie Campagna-Slater, Director of Scientific Education, Chemical Computing Group
12:00-13:00
Workshop Lunch
THURSDAY, May 8 - Scientific Presentations
Afternoon Sessions
THURSDAY, May 8 - Afternoon Sessions
Scientific Presentations
12:30-13:30
Registration (check-in/badge pick-up)
13:30-13:35
Opening Remarks
David Thompson, Chemical Computing Group
CHAIR: Naomi Rajapaksa, Septerna
13:35-14:05
Discovery of Potent and Selective CDK2 Inhibitors Utilizing a Novel Molecular Dynamics Based Approach
Vishal Verma, Senior Principal Scientist, Genentech
14:05-14:35
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer
Ryan Quiroz, Associate Principal Scientist, Discovery Chemistry, Merck
14:35-15:05
Designing Selective α4β7 Inhibitors: Isosteric Replacements Unlock New Avenues for the Treatment of Inflammatory Bowel Disease
Peter Blomgren, Principal Scientist, Gilead Sciences
15:05-15:35
Pharmacophore Creation Strategies: Human vs. Machine
Anh-Tien Ton, Senior Applications Scientist, Chemical Computing Group
15:35-16:05
Afternoon Break
CHAIR: Zach Brill, Merck
16:05-16:35
A Structural and Energetic Analysis of the Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAPDeleted Cancers
Thomas Bobinski, Director, Medicinal Chemistry, CervelloTX
16:35-17:05
Linker Optimization Using Ternary Complex Modeling for the Development of Potent IRAK4 Degraders
Ryan Pemberton, Principal Scientist, Computational Chemistry, Nurix Therapeutics
17:05-17:35
Structure-Guided Discovery and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Antibody-Drug Conjugate Payloads
Akash Patel, Scientist II, Discovery Chemistry, Merck
17:35-17:45
Closing Remarks
Dan Marshall, Genentech
17:45-18:45
Social Reception